{
    "clinical_study": {
        "@rank": "139621", 
        "arm_group": [
            {
                "arm_group_label": "Intravenous Dose Group 1, 2, and 3", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.3 mg/kg) administered every 14 days"
            }, 
            {
                "arm_group_label": "Subcutaneous Dose Group 1, 2, and 3", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 mg/kg),  administered every14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the optimal route of administration, dose level, and safety of intravenous and\n      subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on\n      hemodialysis."
        }, 
        "brief_title": "A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anemia", 
            "Kidney Failure, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males or females \u2265 18 years of age.\n\n          2. Subjects on at least 6 hours of hemodialysis per week, for at least 12 weeks before\n             screening\n\n          3. Subjects must be on a stable intravenous or subcutaneous dose of Erythropoietin\n             Stimulating Agents (excluding methoxy polyethylene glycol-epoetin beta [Mircera]) to\n             maintain hemoglobin.\n\n          4. A mean predialysis hemoglobin concentration \u2265 10 g/dL (grams per deciliter) to \u2264 12\n             g/dL (\u2265 100 g/L (grams per liter) to \u2264 120 g/L) obtained from three consecutive days.\n\n        4.   A Body Mass Index value \u2265 18.5 kg/m2 (kilograms per m2) at screening. 5.   Understand\n        and voluntarily sign an informed consent document prior to       any study related\n        assessments/procedures are conducted.\n\n        6.  Able to adhere to the study visit schedule and comply with all protocol requirements.\n\n        Exclusion Criteria:\n\n          1. Non renal causes of anemia\n\n          2. Subjects on peritoneal dialysis.\n\n          3. Systemic hematological disease\n\n          4. Uncontrolled diabetes mellitus (HbA1c (hemoglobin A1c) > 9%) at screening.\n\n          5. Uncontrolled hypertension defined as mean of home systolic blood pressure > 160 mm Hg\n             (millimeter of mercury) or mean of home diastolic blood pressure > 90 mm Hg\n             calculated once during the screening period prior to randomization\n\n          6. Subjects with heart failure\n\n          7. History of malignancy (except excised and cured non-melanoma skin cancer, or cervical\n             carcinoma in situ that was surgically ablated more than 5 years ago).\n\n          8. Anticipated or scheduled living donor renal transplant during the course of the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999582", 
            "org_study_id": "ACE-011-REN-002", 
            "secondary_id": "2012-003788-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intravenous Dose Group 1, 2, and 3", 
                "description": "Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.", 
                "intervention_name": "Sotatercept", 
                "intervention_type": "Biological", 
                "other_name": "ACE-011"
            }, 
            {
                "arm_group_label": "Subcutaneous Dose Group 1, 2, and 3", 
                "description": "Sotatercept is dosed subcutaneously every 14 days.  The dose a subject receives will depend on the randomization arm and the dose group.", 
                "intervention_name": "Sotatercept", 
                "intervention_type": "Biological", 
                "other_name": "ACE-011"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hematinics"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Anemia", 
            "End Stage Kidney Disease", 
            "Chronic Kidney Disease", 
            "Dialysis", 
            "Erythrpoietin Stimulating Agent (ESA)"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baudour", 
                        "country": "Belgium", 
                        "zip": "7331"
                    }, 
                    "name": "Centre Hospitalier EpiCURA - Clinique Louis Caty de Baudour,"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg,"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "CHR de la CITADELLE,"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coburg", 
                        "country": "Germany", 
                        "zip": "96450"
                    }, 
                    "name": "KfH Nierenzentrum Coburg"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "zip": "40210"
                    }, 
                    "name": "Gemeinschaftspraxis und Dialysezentrum Karlstra\u00dfe"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "8084"
                    }, 
                    "name": "KfH Nierenzentrum"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosenheim", 
                        "country": "Germany", 
                        "zip": "83022"
                    }, 
                    "name": "KfH Nierenzentrum Rosenheim"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Faro", 
                        "country": "Portugal", 
                        "zip": "8000"
                    }, 
                    "name": "Nephrocare Faro"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lisboa", 
                        "country": "Portugal", 
                        "zip": "1649-035"
                    }, 
                    "name": "Hospital de Santa Maria"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portim\u00e3o", 
                        "country": "Portugal", 
                        "zip": "8500-311"
                    }, 
                    "name": "Nephrocare Portim\u00e3o"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Almeria", 
                        "country": "Spain", 
                        "zip": "04009"
                    }, 
                    "name": "Complejo Hospitalario de Torrec\u00e1rdenas."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic of Barcelona"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Universitari Vall d'Hebron"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galdakao", 
                        "country": "Spain", 
                        "zip": "48960"
                    }, 
                    "name": "Hospital Galdakao-Usansolo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "Hospital General Universitario Gregorio Mara\u00f1on"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital 12 de Octubre, Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrevieja (Alicante)", 
                        "country": "Spain", 
                        "zip": "03186"
                    }, 
                    "name": "Hospital de Torrevieja"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "zip": "G11 6NT"
                    }, 
                    "name": "Glasgow Royal Infirmary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW17 0QT"
                    }, 
                    "name": "St. George's Healthcare NHS Trust"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Germany", 
                "Portugal", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Multicenter, Randomized, Open-Label , Multiple-Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects With End-Stage Kidney Disease on Hemodialysis Switched From Erythropoiesis Stimulating Agents With Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group, Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: To Evaluate the Pharmacokinetics, Safety, Tolerability, Efficacy, Dosing Regimen, and Pharmacodynamics of Sotatercept", 
        "overall_contact": {
            "email": "daversa@celgene.com", 
            "last_name": "Daniel Aversa, BS", 
            "phone": "1-732-652-5671"
        }, 
        "overall_contact_backup": {
            "email": "ycoker@celgene.com", 
            "last_name": "Yemisi Coker, Bsc (Hons)", 
            "phone": "+41 32 729 8754"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "William Smith, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Maximum observed concentration in serum", 
                "measure": "Pharmacokinetics (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Time to maximum concentration", 
                "measure": "Pharmacokinetics (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Area under the concentration-time curve", 
                "measure": "Pharmacokinetics (AUC 28d)", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Terminal half life", 
                "measure": "Pharmacokinetics (t1/2,z)", 
                "safety_issue": "No", 
                "time_frame": "211 days"
            }, 
            {
                "description": "treatment emergent adverse sevents (TEAEs) and number of subjects with TEAEs.", 
                "measure": "Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "211 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999582"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in mean hemoglobin concentration between baseline and day 113", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "113 days"
            }, 
            {
                "description": "Change in serum bone biomarker concentrations between baseline and end of study (day 211)", 
                "measure": "Bone Turnover", 
                "safety_issue": "No", 
                "time_frame": "211 days"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}